HARVARD BIOSCIENCE INC HBIO

About HARVARD BIOSCIENCE INC (HBIO): stock profile, AI score and financials

HARVARD BIOSCIENCE INC (HBIO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HBIO at 29.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,502 of 2,925 stocks — the bottom half of the AI-ranked universe. HBIO scores in the top quartile across institutional flow (99.4). Areas of concern include revenue growth (11.5) and revenue scale (14.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 37.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), HARVARD BIOSCIENCE INC reports quarterly revenue of $22.7M, net income of $-2.9M, an operating margin of -4.3%. Top institutional holders of HBIO by reported 13-F value include WEBER CAPITAL MANAGEMENT, Meros Investment Management, ACADIAN ASSET MANAGEMENT, based on the most recent SEC filings. HBIO trades on the Nasdaq exchange and files with the SEC under CIK 1123494. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HARVARD BIOSCIENCE INC directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1123494 →